Compositions and methods of using modified release solabegron for lower urinary tract symptoms

A method for treating LUTS in a patient in need thereof, comprising:

• administering once a day to the patient a pharmaceutical composition for the delivery of a therapeutically effective amount of solabegron, comprising:
• an immediate release composition, comprising solabegron and at least one pharmaceutically acceptable carrier or diluent;
• and a delayed release composition, comprising solabegron and at least one pharmaceutically acceptable carrier or diluent to the patient, wherein the immediate release composition achieves a first plasma Cmax, the delayed release composition achieves a second plasma Cmax, a first plasma Cmin is achieved after the first plasma Cmax and before the second plasma Cmax and a second plasma Cmin is achieved after the second plasma Cmax;
• wherein the first plasma Cmax is about 0.5 ug/ml to about 4.0 ug/ml in about 0.75 to about 4 hours after administration of the pharmaceutical composition;
• wherein the first plasma Cmin is about 0.25 ug/ml to about 1.5 ul/ml in about 4 to about 8 hours after administration of the pharmaceutical composition;
• wherein the second plasma Cmax is about 0.5 ug/ml to about 4 ug/ml in about 2 to about 8 hours after the first plasma Cmin;
• wherein the second plasma Cmin is about 0.01 ug/ml to about 1.0 ug/ml before about 24 hours after administration of the pharmaceutical composition;
• wherein the pharmaceutical composition reduces desensitization of the beta-3 adrenoceptor, when compared to an immediate release pharmaceutical composition of solabegron administered twice daily.